Company: DMAC
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001437749-25-026207
Chunk: 17

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 2
Chunk 17
---
         $(526         )       $(757          )        $(1,123       )
Research and Development Expenses
 
R&D expenses increased to $5.8 million for the three months ended June 30, 2025, up from $3.9 million for the three months ended June 30, 2024. R&D expenses increased to $11.5 million for the six months ended June 30, 2025, up from $7.6 million for the six months ended June 30, 2024. The increases are primarily due to cost increases driven by the continuation of our ReMEDy2 clinical trial, including our global expansion; the expansion of our clinical team in the prior and current year periods and increased manufacturing development activity. These increases were partially offset by cost reductions related to in-use study work performed and completed in the prior year period. We expect that our R&D expenses will moderately increase in future periods relative to recent prior periods as we continue our ReMEDy2 trial, including our global expansion and continue the expansion of our DM199 clinical development program into PE.
General and Administrative Expenses
 
G&A expenses were $2.2 million and $1.7 million for the three months ended June 30, 2025 and 2024, respectively. G&A expenses were $4.7 million and $3.8 million for the six months ended June 30, 2025 and 2024, respectively. These increases resulted primarily increased non-cash share-based compensation expense and increased personnel costs incurred in conjunction with expanding our team, partially offset by a reduction in legal fees incurred in connection with our lawsuit against PRA Netherlands. We expect G&A expenses to remain steady in future periods as compared to recent prior periods.
Other Income, Net
 
Other income, net, was $313 thousand and $526 thousand for the three months ended June 30, 2025 and 2024, respectively, and $757 thousand and $1.1 million for the six months ended June 30, 2025 and 2024, respectively. The decreases were driven by reduced interest income recognized during the current year period related to lower average marketable securities balances during the current year period as compared to the prior year period.
 
   17

  

Liquidity and Capital Resources
 
The following tables summarize our liquidity and capital resources as of June 30, 2025 and December 31, 2024, and our cash flows for each of the six month periods ended June 30